Title | Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: Comparison with conventional DCE-MRI. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Zhang J, Winters K, Kiser K, Baboli M, Kim SGene |
Journal | PLoS One |
Volume | 15 |
Issue | 6 |
Pagination | e0234520 |
Date Published | 2020 |
ISSN | 1932-6203 |
Keywords | Animals, Antineoplastic Agents, Bevacizumab, Cell Line, Tumor, Contrast Media, Fluorouracil, Gadolinium DTPA, Magnetic Resonance Imaging, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Experimental, Sensitivity and Specificity |
Abstract | PURPOSE: To investigate the validity of contrast kinetic parameter estimates from Active Contrast Encoding (ACE)-MRI against those from conventional Dynamic Contrast-Enhanced (DCE)-MRI for evaluation of tumor treatment response in mouse tumor models. METHODS: The ACE-MRI method that incorporates measurement of T1 and B1 into the enhancement curve washout region, was implemented on a 7T MRI scanner to measure tracer kinetic model parameters of 4T1 and GL261 tumors with treatment using bevacizumab and 5FU. A portion of the same ACE-MRI data was used for conventional DCE-MRI data analysis with a separately measured pre-contrast T1 map. Tracer kinetic model parameters, such as Ktrans (permeability area surface product) and ve (extracellular space volume fraction), estimated from ACE-MRI were compared with those from DCE-MRI, in terms of correlation and Bland-Altman analyses. RESULTS: A three-fold increase of the median Ktrans by treatment was observed in the flank 4T1 tumors by both ACE-MRI and DCE-MRI. In contrast, the brain tumors did not show a significant change by the treatment in either ACE-MRI or DCE-MRI. Ktrans and ve values of the tumors from ACE-MRI were strongly correlated with those from DCE-MRI methods with correlation coefficients of 0.92 and 0.78, respectively, for the median values of 17 tumors. The Bland-Altman plot analysis showed a mean difference of -0.01 min-1 for Ktrans with the 95% limits of agreement of -0.12 min-1 to 0.09 min-1, and -0.05 with -0.37 to 0.26 for ve. CONCLUSION: The tracer kinetic model parameters estimated from ACE-MRI and their changes by treatment closely matched those of DCE-MRI, which suggests that ACE-MRI can be used in place of conventional DCE-MRI for tumor progression monitoring and treatment response evaluation with a reduced scan time. |
DOI | 10.1371/journal.pone.0234520 |
Alternate Journal | PLoS One |
PubMed ID | 32520950 |
PubMed Central ID | PMC7286489 |
Grant List | P30 CA016087 / CA / NCI NIH HHS / United States S10 OD018337 / OD / NIH HHS / United States R01 CA160620 / CA / NCI NIH HHS / United States R01 CA219964 / CA / NCI NIH HHS / United States P41 EB017183 / EB / NIBIB NIH HHS / United States |
Related Institute:
MRI Research Institute (MRIRI)